Decitabine

Name: Decitabine
Brand: Selleck Chemicals
SKU: S1200
Rating: 5 (77 reviews)

For research use only.

Catalog No.S1200 Synonyms: Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine

77 publications

CAS No. 2353-33-5

Decitabine (Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

Selleck's Decitabine has been cited by 77 publications

Nat Biotechnol, 2019, 10.1038/s41587-019-0372-z

PubMed: 31873215 ( click the link to review the publication )

Nat Med, 2019, 25(7):1073-1081

PubMed: 31270502 ( click the link to review the publication )

Cancer Discov, 2019, 9(1):34-45

PubMed: 30297358 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell Metab, 2019, 29(4):886-900

PubMed: 30661930 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):906-921

PubMed: 30537513 ( click the link to review the publication )

Nat Commun, 2020, 6;11(1):740

PubMed: 32029739 ( click the link to review the publication )

Oncogene, 2020, 11

PubMed: 32393833 ( click the link to review the publication )

J Cancer, 2020, 28;11(10):2874-2886

PubMed: 32226505 ( click the link to review the publication )

Oncogenesis, 2020, 13;9(5):48

PubMed: 32404892 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(9):5260-5273

PubMed: 32227582 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Int J Oncol, 2020, 56(6):1429-1441

PubMed: 32236593 ( click the link to review the publication )

JCI Insight, 2020, 5(11):e137569

PubMed: 32493845 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11396

PubMed: 32647280 ( click the link to review the publication )

Clin Sci (Lond), 2020, 134(2):273-287

PubMed: 31957803 ( click the link to review the publication )

Genes Chromosomes Cancer, 2020, 10.1002/gcc.22884

PubMed: 32614991 ( click the link to review the publication )

Genet Test Mol Biomarkers, 2020, 24(7):399-408

PubMed: 32551898 ( click the link to review the publication )

Cancer Manag Res, 2020, 12:6665-6677

PubMed: 32801900 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2020, 10.1111/1440-1681.13390

PubMed: 32754907 ( click the link to review the publication )

Am J Transl Res, 2020, 12(7):3461-3475

PubMed: 32774712 ( click the link to review the publication )

Mol Ther Oncolytics, 2020, 18:282-294

PubMed: 32728616 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4155-4167

PubMed: 30952643 ( click the link to review the publication )
Theranostics, 2019, 9(9):2424-2438

PubMed: 31131045 ( click the link to review the publication )

Theranostics, 2019, 9(21):6175-6190

PubMed: 31534544 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2761-2774

PubMed: 30877105 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Death Differ, 2019, 26(5):843-859

PubMed: 29988076 ( click the link to review the publication )

J Nucl Med, 2019, 10.2967/jnumed.118.224048

PubMed: 30796167 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12849

PubMed: 31758842 ( click the link to review the publication )

Signal Transduct Target Ther, 2019, 4:51

PubMed: 31815008 ( click the link to review the publication )

ACS Chem Biol, 2019, 14(3):348-355

PubMed: 30763062 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):1813-1826

PubMed: 30883132 ( click the link to review the publication )

J Cell Physiol, 2019, 234(8):14040-14049

PubMed: 30623427 ( click the link to review the publication )

Eur J Nutr, 2019, 10.1007/s00394-019-01925-6

PubMed: 30762097 ( click the link to review the publication )

Biomed Pharmacother, 2019, 112:108699

PubMed: 30970511 ( click the link to review the publication )

Front Genet, 2019, 10:422

PubMed: 31130994 ( click the link to review the publication )

Life Sci, 2019, 218:241-252

PubMed: 30586565 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):202

PubMed: 30841886 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.06.097

PubMed: 31277942 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-04892-7

PubMed: 31147860 ( click the link to review the publication )

Sci Rep, 2019, 9(1):16970

PubMed: 31740746 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3164

PubMed: 30089774 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Leukemia, 2018, 32(4):900-910

PubMed: 29249821 ( click the link to review the publication )

Theranostics, 2018, 8(16):4520-4534

PubMed: 30214636 ( click the link to review the publication )
J Hematol Oncol, 2018, 11(1):62

PubMed: 29728108 ( click the link to review the publication )

Oncoimmunology, 2018, 7(10):e1484981

PubMed: 30288346 ( click the link to review the publication )

J Gastroenterol, 2018, 53(1):71-83

PubMed: 28315004 ( click the link to review the publication )

Oncogenesis, 2018, 7(11):91

PubMed: 30467308 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):696-706

PubMed: 29453320 ( click the link to review the publication )

Antimicrob Agents Chemother, 2018, 62(9)

PubMed: 29914957 ( click the link to review the publication )

Cancer Immunol Immunother, 2018, 67(2):237-246

PubMed: 29058035 ( click the link to review the publication )

Biomed Pharmacother, 2018, 104:204-210

PubMed: 29772441 ( click the link to review the publication )

Leuk Res, 2018, 64:34-41

PubMed: 29175379 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2304-2314

PubMed: 28729399 ( click the link to review the publication )

Br J Haematol, 2017, 10.1111/bjh.14707

PubMed: 28439875 ( click the link to review the publication )

J Biol Chem, 2017, 292(31):12842-12859

PubMed: 28634230 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2017, 143(11):2189-2200

PubMed: 28730284 ( click the link to review the publication )

Am J Transl Res, 2017, 9(2):454-465

PubMed: 28337274 ( click the link to review the publication )

Alcohol, 2017, 60:95-101

PubMed: 28433417 ( click the link to review the publication )

Oncotarget, 2017, 8(34):56802-56815

PubMed: 28915632 ( click the link to review the publication )

Oncotarget, 2017, 8(51):89182-89193

PubMed: 29179510 ( click the link to review the publication )

Nat Commun, 2016, 7:11040

PubMed: 27010513 ( click the link to review the publication )

Mol Cell Biochem, 2016, 415(1-2):197-205

PubMed: 27000860 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Cancer Res, 2015, 75(15):2987-98

PubMed: 26122843 ( click the link to review the publication )

J Immunol, 2015, 10.4049/jimmunol.1403196

PubMed: 25825452 ( click the link to review the publication )

Cell Cycle, 2015, 10.1080/15384101.2015.1044174

PubMed: 25946202 ( click the link to review the publication )

Oncol Lett, 2015, 9(4):1691-1698

PubMed: 25789025 ( click the link to review the publication )
Cancer Immunol Res, 2015, 3(9):1030-41

PubMed: 26056145 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4143-64

PubMed: 25202123 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Exp Hematol, 2014, 42(7):536-46

PubMed: 24704162 ( click the link to review the publication )

Leuk Res, 2014, 38(3):402-10

PubMed: 24484870 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description

Targets

DNA methylation ^[1]
(HL-60, KG1a cells)

In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. ^[1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [³H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Eca109	M37vPGZ2dmO2aX;uJGF{e2G7	M3LwfVAvPcLizszN	MorCNlQhcA>?	MVP3ZZRmeg>?	MUXtc4R2dGG2ZYOgeIhmKGenbnWg[ZhxemW\|c3nvckBw\iCPQVfFMWEhdWWvYnXydy=>	NIPXT2UzPTF{M{C4Ni=>
Eca109	NFTZWnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITNSGIxNjVxMj61M\|Uh\|ryP	MlrHNlQwPDhxN{KgbC=>	M2XIVJdifGW{	NXXlU4RQcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=>	NWSwWpp7OjVzMkOwPFI>
Eca109	MWDGeY5kfGmxbjDBd5NigQ>?	NYTEbHc1OC53wrFOwG0>	M{\2TVYwOTJxMkSgbC=>	NXy1O5p3f2G2ZYK=	MX\pcohq[mm2czDj[YxtKG2rZ4LheIlwdsLi	NWX5fYFlOjVzMkOwPFI>
Eca109	MVnGeY5kfGmxbjDBd5NigQ>?	M2rkflAvPcLizszN	MoOzNlQhcA>?	M4HDWpdifGW{	NGj0UpJqdmirYnn0d{Bk\WyuIHnueoF{cW:w	MlrwNlUyOjNyOEK=
Eca109	NVvBfIRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXOwMlXDqM7:TR?=	NHfpS4QzPCCq	MoLre4F1\XJ?	NUTIWoo{cW6mdXPld{BIOi:PIHHydoV{fCCrbjD0bIUh[2WubDDjfYNt\Q>?	NVTtbWhXOjVzMkOwPFI>
Eca109	M2TDbWZ2dmO2aX;uJGF{e2G7	MoLlNE42NzFizszN	M3K3Z\|I1KGh?	Mn3te4F1\XJ?	NH7Id5Bl\WO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDOSk3PwkJ{IHHu[EBOVVB{	M2HYcVI2OTJ\|MEiy
SW1116	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrOd2ZHOC53L{GvNk82KM7:TR?=	MkPDOFghcA>?	M{LGcWROW09?	NF\1dolmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v	M3XBOlI1QDd2Mki2
LOVO	NYXuOWJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPHNE42NzFxMj:1JO69VQ>?	Ml71OFghcA>?	M4P5TWROW09?	M3S2eoVvcGGwY3XzJJRp\SCJZX\peIlvcWJiaX7keYNm\CClZXzsJIlvcGmkaYTpc44>	MVKyOFg4PDJ6Nh?=
SW1116	NYqxO2trTnWwY4Tpc44hSXO\|YYm=	NXK2[I5POTBizszN	MmOxOFghcA>?	NWLCXWFmTE2VTx?=	MnzSbY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm\|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj	NEDOcnIzPDh5NEK4Oi=>
LOVO	M2i2fGZ2dmO2aX;uJGF{e2G7	M1foRlExKM7:TR?=	Ml7GOFghcA>?	NFXzR2NFVVOR	MljSbY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm\|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj	M{LjTlI1QDd2Mki2
SW1116	MWrBdI9xfG:\|aYOgRZN{[Xl?	MkG1NVAh\|ryP	NEK5eYs1QCCq	M3j2SGROW09?	NHLVVllmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM>	MXuyOFg4PDJ6Nh?=
LOVO	NV30PYNUSXCxcITvd4l{KEG\|c3H5	M1jEPVExKM7:TR?=	Mlf0OFghcA>?	MknZSG1UVw>?	Mm\D[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz	MonuNlQ5PzR{OE[=
RPMI-8226	MoD3RZBweHSxc3nzJGF{e2G7	MnvONU8zKM7:TR?=	M3O2WlQ5Nzd{L{m2JIg>	NEOwRXBFVVOR	MmPXbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	MUCyOFg{OzFyOB?=
OPM-2	NHj6doZCeG:ydH;zbZMhSXO\|YYm=	MoLrNU8zKM7:TR?=	NYPsUYJvPzJxOU[vNVIxKGh?	M4XsWmROW09?	MXTpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MnnyNlQ5OzNzMEi=
JJN3	MoPXRZBweHSxc3nzJGF{e2G7	MUewMlUwOSEQvF2=	NVrS[oR2OjRxNEigbC=>	NE\JNJpFVVOR	NH[2RVhqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	MmT2NlQ5OzNzMEi=
NCI-H929	NXHISIFwSXCxcITvd4l{KEG\|c3H5	NV\0XZlVOS9{IN88US=>	MXO3Nk86Pi9zMkCgbC=>	MVnEUXNQ	NWjvPFRvcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	M{XE[FI1QDN\|MUC4
RPMI-8226	NEHiTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVT4WYRbOS9{IN88US=>	M2LNWFI1NzR6L{eyJIg>	MojLSG1UVw>?	MU\h[oZm[3S\|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>?	NIHrR2QzPDh\|M{GwPC=>
OPM-2	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXqxM\|Ih\|ryP	M3jRXVI1NzR6L{eyJIg>	NGrpbm5FVVOR	NVHpN5Bv[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm=	NHL4UFQzPDh\|M{GwPC=>
JJN3	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjQWWFKOC53L{Gg{txO	MonaNlQwPDhxN{KgbC=>	MXzEUXNQ	MXHh[oZm[3S\|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>?	NXHL[npsOjR6M{OxNFg>
NCI-H929	MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfyNU8zKM7:TR?=	Mkf6NlQwPDhxN{KgbC=>	M33w[WROW09?	M1zSO4Fn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7	MXSyOFg{OzFyOB?=
HeLa	MYDLbY5ie2ViQYPzZZk>				NX\OVVdzU2l;MUCwNQKBmzVyMECg{txOKG[xcjDoSW5VOQ>?	NYfJUmtwOjR5OECwPVg>
HeLa	NHnY[5BMcW6jc3WgRZN{[Xl?				NWLWenVTU2l;NT62JOKyKDBwNTFOwG0h\m:{IHjFUnQz	NX6yNZNlOjR5OECwPVg>
HeLa	NGPpVo5McW6jc3WgRZN{[Xl?				Ml;FT4k:OjFwNjFCtUA{NjBizszNJIZweiCqQ17UNS=>	M3HzUFI1PzhyMEm4
HeLa	M{j1UGtqdmG\|ZTDBd5NigQ>?				Mo\hT4k:OTRwNDFCtUA1NjZizszNJIZweiCqQ17UNy=>	NVLMOmRQOjR5OECwPVg>
NB4	MkHhSpVv[3Srb36gRZN{[Xl?	M{fjeVIvPS93L{euOU8yOCEQvF2=	MVuyOEBp	NXfCNmdUTE2VTx?=	NX3Rd5V1cW6lcnXhd4ViKHSqZTDlfJBz\XO\|aX;uJI9nKHC{ZXP1dpNweiCvaWKtNVI2[Q>?	M2fmdlI1PDh2OEew
CD4+ CD25− T	M{\KNGZ2dmO2aX;uJGF{e2G7	NFfwZZMyNzVizszN			M4PGNZJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>?	NIK2flAzPDR5NkO2NC=>
BV-173	MknNRZBweHSxc3nzJGF{e2G7	MnPpNE4zPS9yLkWvNE44PS9zIN88US=>	MkL6OFgwPzJxOU[gbC=>	M4fGNuKhWEKV	MXvpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:\|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK=	M2PIS\|I1PDJ\|NkGz
ML-1	MUnBdI9xfG:\|aYOgRZN{[Xl?	MUKwMlI2NzBwNT:wMlc2NzFizszN	Mn3mOFgwPzJxOU[gbC=>	MUhCpHBDWw>?	NVHDW\|E{cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz	NWjkNlgxOjR2MkO2NVM>
HL-60	NEDzZ3JCeG:ydH;zbZMhSXO\|YYm=	NIPIN5YxNjJ3L{CuOU8xNjd3L{Gg{txO	Moe0OFgwPzJxOU[gbC=>	MWlCpHBDWw>?	NELIVnhqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI>	MnvBNlQ1OjN4MUO=
KG-1a	M4fYbGFxd3C2b4Ppd{BCe3OjeR?=	MWqwMlI2NzBwNT:wMlc2NzFizszN	M{PkeVQ5Nzd{L{m2JIg>	NGfBUnHDqFCEUx?=	Ml3DbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy	M1;XeVI1PDJ\|NkGz
BV-173	MXLGeY5kfGmxbjDBd5NigQ>?	M{iwOVI2OC93MEDuUS=>	NHW2[\|M1QCCq	MURCpHBDWw>?	MV7pcoR2[2W\|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V?	MoH6NlQ1OjN4MUO=
CEM	NUm2c5I5TnWwY4Tpc44hSXO\|YYm=	MlzINlUxNzVyMH7N	MX[0PEBp	MVhCpHBDWw>?	NVryXWdicW6mdXPld{Bl\WyjeXXkJIFv\CC\|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl	MkfWNlQ1OjN4MUO=
HL-60	NVW0NFd1TnWwY4Tpc44hSXO\|YYm=	NXriOVA2OjVyL{WwNI5O	MYm0PEBp	NV;RfWlvyqCSQmO=	M3jNPIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W\|dHHpcoVlKFKRUzDpcoNz\WG\|ZR?=	MYWyOFQzOzZzMx?=
ML-1	NFjuSoZHfW6ldHnvckBCe3OjeR?=	Mn\0NlUxNzVyMH7N	NIDXU\|U1QCCq	M2f5fOKhWEKV	NWLuUY1lcW6mdXPld{Bl\WyjeXXkJIFv\CC\|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl	NITyPFQzPDR{M{[xNy=>
DLD-1	MX7GeY5kfGmxbjDBd5NigQ>?	MmPsNlUxNzVyMH7N	MnrKOFghcA>?	NWXMc2VTyqCSQmO=	MVHkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm	M2rYT\|I1PDJ\|NkGz
HCT-116	Ml7iSpVv[3Srb36gRZN{[Xl?	MUmyOVAwPTBybl2=	NEHFNXM1QCCq	MV1CpHBDWw>?	NHnsenRldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn	MV2yOFQzOzZzMx?=
U937-A/E-9/14/18	NF7ySnNCeG:ydH;zbZMhSXO\|YYm=	MV2wMlAyNzBwMT:xM\|ExKM7:TR?=	MX60PEBp		MWHpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M{nvcVI1OzByNEW2
HT29	NHuwfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWG3NkBp		M{PZSGlEPTB;MUSwNOKyOTd7IN88US=>	NYPjcpZmOjRzN{KwOlE>
SW48	NVHEbFFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWG3NkBp		MlfCTWM2OD1zNT6yxtE3NjJizszN	MkewNlQyPzJyNkG=
HCT116	NGrtRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHvVZ3I4OiCq		NGHmdphKSzVyPUGuO:KyOC52IN88US=>	NHzhN3YzPDF5MkC2NS=>
HepG2	NF30dWJHfW6ldHnvckBCe3OjeR?=	MWWwMlUwOSEQvF2=	M33RWVI1KGh?	NFjzbZFFVVOR	M1;BfpVxNXKnZ4XsZZRm\CC2aHWgdoVt[XSrdnWgU2NVVjJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w	NHXLV2gzPDF2Nki3OC=>
LS174T	NVfIc\|FrTnWwY4Tpc44hSXO\|YYm=	NWewT4l6OC53L{Gg{txO	MUKyOEBp	MUHEUXNQ	MkHIcIVi\CC2bzDhckBqdmO{ZXHz[UBw\iCRQ2TONkBt\X[nbIO=	MojaNlQyPDZ6N{S=
HepG2	NXfsVolESXCxcITvd4l{KEG\|c3H5	Mm\nNU8yOC9zMECg{txO	M1;xOFch\A>?	NEDlNppFVVOR	MXTpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M{O0O\|I1OTR4OEe0
LS174T	NInEUGtCeG:ydH;zbZMhSXO\|YYm=	MX[xM\|ExNzFyMDFOwG0>	MlnTO{Bl	MV7EUXNQ	NV7pW4NMcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NYrN[lFVOjRzNE[4O\|Q>
QBC-939	NFzWPYJCeG:ydH;zbZMhSXO\|YYm=	M2q0TVEwOTBxMUCwJO69VQ>?	MofkO{Bl	MknqSG1UVw>?	MlTTbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MWGyOFE1Pjh5NB?=
U251	NXHNcZJpSXCxcITvd4l{KEG\|c3H5	M{XtUFEwOTBxMUCwJO69VQ>?	NXPWTIlKPyCm	NIXCT2pFVVOR	NUXEdplpcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NEXxVZAzPDF2Nki3OC=>
HL-60	NWfydoVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3XV4kyKM7:TR?=	NYjYPJZtPDhiaB?=		MkO5bY5kemWjc3XzJGczNXCqYYPlJINmdGxiZoLhZ5Rqd25?	NI\KVngzPDByMEOyOC=>
MDA‑MB‑453	NIrKO2NHfW6ldHnvckBCe3OjeR?=	MVywMlIwOSEQvF2=	MkLCO\|IhcA>?		MV3jZZV{\XNicnWt[ZhxemW\|c3nvckBw\iClbHH1[IlvyqBzwrC=	M3nhbFI{QDR2MkK4
HCC1569	MlW3SpVv[3Srb36gRZN{[Xl?	M2rGXlAvOi9zIN88US=>	NXXTeHY5PzJiaB?=		MY\jZZV{\XNicnWt[ZhxemW\|c3nvckBw\iClbHH1[IlvyqBzwrC=	NHfvWIMzOzh2NEKyPC=>
BT‑474	MYfGeY5kfGmxbjDBd5NigQ>?	NHTxN4kxNjJxMTFOwG0>	MY[3NkBp		NHvmVXNk[XW\|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA>	M{TVXlI{QDR2MkK4
AGS	MXLBdI9xfG:\|aYOgRZN{[Xl?	MW[1M\|ExNzJyL{WwJO69VQ>?	M1TxN\|Q5yqCqwrC=	Mm\0SG1UVw>?	MXTpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=>	MYWyN\|U5Ojd6NB?=
A549	NXryZlhzSXCxcITvd4l{KEG\|c3H5	NEDBcpQ2NzFyL{KwM\|UxKM7:TR?=	NXnZTWczPDkEoHlCpC=>	NWL0OnAxTE2VTx?=	NXPuVXpMcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB?	MlTNNlM2QDJ5OES=
AGS	MmDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIn3TYU2NzFyL{KwM\|UxKM7:TR?=	NWq5N3FQPDkEoHlCpC=>	NEHBb3ZFVVOR	MXvpcoR2[2W\|IFeyM20heGijc3WgZZJz\XO2wrC=	MorBNlM2QDJ5OES=
Kasumi-1	NHi2Z3NCeG:ydH;zbZMhSXO\|YYm=	MXWwMlUh\|ryP	NGPNN4o1QMLiaNMg		M1eyeIRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj	NG\odmwzOzR7M{O0PC=>
OCI-AML3	NVPa[Gd1SXCxcITvd4l{KEG\|c3H5	MXeyMlUh\|ryP	MmHxOFjDqGkEoB?=		MnrU[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O=	M{nWU\|I{PDl\|M{S4
MV4-11	MnLnRZBweHSxc3nzJGF{e2G7	MojqNk42KM7:TR?=	MljWOFjDqGkEoB?=		M3O2TYRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj	MV6yN\|Q6OzN2OB?=
NK	MlPHR5l1d3SxeHn0fUBCe3OjeR?=	Mmm2NE4xOi1{MDFOwG0>	NWPadnEzPSCm		Mn7U[IVkemWjc3XzJJRp\SCleYTvcJl1cWNiYXP0bZZqfHlib3[gUmsh[2WubIOgZZQhcW62ZYLt[YRq[XSnIHPvcoNmdnS{YYTpc45{KHKnc4XseIlv\yCrbjDhJHUue2ijcHXkJIRwe2YkgKPy[ZNxd26\|ZTDjeZJ3\Q>?	NVXocVQ3OjN\|MkiwPFg>
NK	MYTBdI9xfG:\|aYOgRZN{[Xl?	MoXuNE4xOi1{MDFOwG0>	NYjYcmdPPSCm		NXrBTHdz\GWlcnXhd4UhVktiY3XscEBxem:uaX\ldoF1cW:wIHHu[EB3cWGkaXzpeJkh[XNidHjlJINwdmOnboTyZZRqd25iaX7jdoVie2Wm	NU\JTY43OjN\|MkiwPFg>
NK	NGrPSVFHfW6ldHnvckBCe3OjeR?=	MlLXNE4xOS1{MDFOwG0>	NEDofVQ2KGR?		Mm\6Z4F2e2W\|IHj5dI9u\XSqeXzheIlwdiCxZjDOT{Bk\WyuczDpckBiKGSxc3ZihLNz\XOyb37z[S=>	M4KyelI{OzJ6MEi4
MOLT4/DNR	MmGzSpVv[3Srb36gRZN{[Xl?	NVzPd2FTPSEQvF2=	Mn24OEBl		MnjydoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44>	MXSyN\|A3ODV5MB?=
Jurkat/DOX	MojzSpVv[3Srb36gRZN{[Xl?	NVnBeVNWPSEQvF2=	M3\FVVQh\A>?		M1HxRpJm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v	M2jnbFI{ODZyNUew
MOLT4/DNR	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXf5c4xDPSEQvF2=	M13YVlQh\A>?		MnvadoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC\|ZX7zbZRqfmm2eR?=	NVPESW0xOjNyNkC1O\|A>
Jurkat/DOX	M3XKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nuTVUh\|ryP	NFzUc\|E1KGR?		NHW2N2xz\WS3Y3XzJJRp\SCLQ{WwxsB3[Wy3ZTDmc5Ih\GG3bn;yeYJq[2mwIIPlcpNqfGm4aYT5	MUOyN\|A3ODV5MB?=
ccRCC	MmW2RZBweHSxc3nzJGF{e2G7	NHjTdI8xNjBzLUGw{txO	NGTRZZE4OiCq	MlPQSG1UVw>?	NFjFcVFp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w	NYj3fFBxOjJ6Mk[0Olc>
TNBC	M4P2ZmFxd3C2b4Ppd{BCe3OjeR?=	MUKwMlAyNTFyzszN	NV;FNGo4PzJiaB?=	NX\uPZJ6TE2VTx?=	MofEbIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>?	NGDpUnczOjh{NkS2Oy=>
A498	NFHnTJVCeG:ydH;zbZMhSXO\|YYm=	NYT6PW5UOC5yMT2xNO69VQ>?	NILVOHo4OiCq	NHvWNHVFVVOR	MmTLbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=>	MXiyNlgzPjR4Nx?=
KIJ265T	M4XhcGFxd3C2b4Ppd{BCe3OjeR?=	NYS3OZFsOC5yMT2xNO69VQ>?	MVu3NkBp	NFnrS3RFVVOR	NF\HPI5qdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv	MmjvNlI5OjZ2Nke=
MDA-231	MoDMRZBweHSxc3nzJGF{e2G7	MWKwMlAyNTFyzszN	M3\WPVczKGh?	NVnoW3RnTE2VTx?=	M1;3bIlv\HWlZYOgd5lv\XKpaYP0bYMhemW\|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4>	NHHIdJAzOjh{NkS2Oy=>
BT-20	NXrDfpl{SXCxcITvd4l{KEG\|c3H5	NGL6U40xNjBzLUGw{txO	MVi3NkBp	NHLZd5RFVVOR	MUjpcoR2[2W\|IIP5coVz\2m\|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu	M{L0elIzQDJ4NE[3
U937	M{m2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnr4OU0zOCEQvF2=	MV:yOE81QC95MjDo		MWjpcoR2[2W\|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy	M2rEeFIzPzZ5MEKx
HL60	M3TVR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LwW\|UuOjBizszN	MWGyOE81QC95MjDo		M2Daeolv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	NYLVc4xpOjJ5NkewNlE>
U937	NWX1VlNuSXCxcITvd4l{KEG\|c3H5	MUKxOUDPxE1?	NVWzWJQyOjRxNEivO\|IhcA>?		NESwUY9qdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	MnLyNlI4PjdyMkG=
HL60	MlWxRZBweHSxc3nzJGF{e2G7	MYSxOUDPxE1?	NUD3eY0zOjRxNEivO\|IhcA>?		MVXpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NXruU5lJOjJ5NkewNlE>
LS411N	M{\2PGFxd3C2b4Ppd{BCe3OjeR?=	NYmwT5FXOC53IN88US=>	NFvOR484OiCq		NIHyb3lqdmO{ZXHz[ZMhTmG\|IH3SUmEhdGW4ZXy=	MV:yNlQ3OTZ7NR?=
MDA-MB-231	Mn3iRZBweHSxc3nzJGF{e2G7	MWSxNEDPxE1?	MkPzOFghcA>?		M2P5dJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MmHiNlE5QDd4OUe=
MCF-7	MnjyRZBweHSxc3nzJGF{e2G7	MYSxNEDPxE1?	M13iOlQ5KGh?		NGPzN41z\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MnXnNlE5QDd4OUe=
A375	NH34NYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmiyNE42KM7:TR?=	MUGxM\|UwQCCm		MX\pcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W\|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>?	NITtRpkzOTd7Nk[yNi=>
SKMEL1	M{nOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlryNE42KM7:TR?=	MVWxM\|UwQCCm		NXi3XVZbcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO=	MVGyNVc6PjZ{Mh?=
SKMEL3	NE\p[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnBdFNIOC53IN88US=>	M2r1V\|EwPS96IHS=		MmTrbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN?	NUK5SZZwOjF5OU[2NlI>
SKMEL28	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4D6fVAvPSEQvF2=	M2TySVEwPS96IHS=		MVHpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W\|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>?	NXfqSXJMOjF5OU[2NlI>
MeWo	NUD2NXJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{L3[lAvPSEQvF2=	NG\tWZUyNzVxODDk		NYDaOohIcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO=	NYT2XGw4OjF5OU[2NlI>
B16	M3fuVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXaNE42KM7:TR?=	MUmxM\|UwQCCm		NXL3[2tTcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO=	NHruU20zOTd7Nk[yNi=>
Ly 1	NXi5d4tzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmfhNlQhcA>?		M4TMR2lEPTB;Nz6zJO69VQ>?	MoPWNlE4PzJyNEm=
Ly 7	NULZeZRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NF3GOpczPCCq		MV\JR\|UxRTFyLkeg{txO	MV:yNVc4OjB2OR?=
Su-DHL6	NUjkR5R4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MX:yOEBp		MXzJR\|Ux97zgMkCg{txO	M2L6OVIyPzd{MES5
Ly 10	NHi1OHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn2wNlQhcA>?		MYjJR\|Ux97zgMkCg{txO	NXPScIRUOjF5N{KwOFk>
RIVA	NXzFOVJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXKyOEBp		NV3MPVQ6UUN3MP-8olIxKM7:TR?=	NEL5T4MzOTd5MkC0PS=>
Su-DHL2	NIDKdZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{LJV\|I1KGh?		MkDiTWM2OO,:nkKwJO69VQ>?	NFr4epUzOTd5MkC0PS=>
Ly 1	M4e5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3r3d\|Q5KGh?		MVnJR\|UxRTBwM{Sg{txO	M2jtdFIyPzd{MES5
Ly 7	M1\uVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mn21OFghcA>?		NXPCVm96UUN3ME2wMlAzPSEQvF2=	NVTR[49{OjF5N{KwOFk>
Su-DHL6	M2PmVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX:0PEBp		M17nUmlEPTExvK6yNEDPxE1?	M1mxNVIyPzd{MES5
Ly 10	NHLxR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2rCNlQ5KGh?		MmTFTWM2OD1zLkig{txO	MVOyNVc4OjB2OR?=
RIVA	NH7KS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4TWbVQ5KGh?		NIHPdZNKSzVy78{eNlAh\|ryP	NWHaNYgyOjF5N{KwOFk>
Su-DHL2	NXva[mRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGnJd3k1QCCq		NWHSc2FnUUN3ME2xO{41KM7:TR?=	M{nJOFIyPzd{MES5
Ly 1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoPLO\|IhcA>?		NEXPdmVKSzVyPUCuNFEh\|ryP	NFfW[mkzOTd5MkC0PS=>
Ly 7	NX;NRpp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYS3NkBp		M1HtTmlEPTB;MD6wNVgh\|ryP	MnnwNlE4PzJyNEm=
Su-DHL6	NGTCSJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn3zO\|IhcA>?		M{S3[2lEPTB;MT62JO69VQ>?	NXz1W402OjF5N{KwOFk>
Ly 10	MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NF;UTYQ4OiCq		MWLJR\|UxRTFwMjFOwG0>	Mnn0NlE4PzJyNEm=
RIVA	M4r1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M33DWFczKGh?		MkXBTWM2OO,:nkKwJO69VQ>?	M1ftTVIyPzd{MES5
Su-DHL2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkDGO\|IhcA>?		NFLKOoZKSzVyPUGxMlIh\|ryP	MWmyNVc4OjB2OR?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Survivin / Bcl-2 / p53 / c-Myc / DNMT1; PubMed: 26384351 Oncotarget HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells. p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; PubMed: 25762617 Oncotarget Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations. phospho-p38 / p38 / phospho-NFκB / NFκB; PubMed: 26617834 Int J Clin Exp Pathol Decitabine suppressed the phosphorylation of p38 and NF-κB. p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; PubMed: 26692933 Am J Transl Res DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments. E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; PubMed: 28152502 Oncotarget The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.	26384351 25762617 26617834 26692933 28152502
Immunofluorescence	DNMT1; PubMed: 21303982 Cancer Res Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain). E-cadherin / MMP-9; PubMed: 28152502 Oncotarget Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC.	21303982 28152502
Growth inhibition assay	Cell viability; PubMed: 26384351 Oncotarget Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.	26384351

In vivo

In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse DNA synthesis assay : The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [³H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:^[1]	- Collapse Cell lines: HL-60 and KG1a Concentrations: 0-500 nM Incubation Time: 96 hours Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice. Dosages: ≤2.5 mg/kg Administration: Administered via i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	45 mg/mL (197.18 mM)
	Water	10 mg/mL (43.81 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): water For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Decitabine SDF

Molecular Weight	228.21
Formula	C₈H₁₂N₄O₄
CAS No.	2353-33-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine
Smiles	C1C(C(OC1N2C=NC(=NC2=O)N)CO)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04086238	Completed	Drug: Decitabine	Healthy	EpiDestiny Inc.	October 8 2019	Phase 1
NCT04113616	Recruiting	Drug: KRT-232\|Drug: Cytarabine\|Drug: Decitabine	Acute Myeloid Leukemia (AML)\|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN)	Kartos Therapeutics Inc.	September 25 2019	Phase 1\|Phase 2
NCT03875287	Recruiting	Drug: Decitabine\|Drug: Cedazuridine	Solid Tumor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Astex Pharmaceuticals Inc.	April 17 2019	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is S1200 a racemic mixture or a monomer?
Answer:
S1200 is R form

Choose Your Country or Region

By Signaling Pathways

By product type

Decitabine